Merck, Schering-Plough Aim To Be Among Top-Five Players In Emerging Markets
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Merck expects to bring more than $2 billion in annual revenue from emerging markets and to meet its goal of reaching the top-five market share in targeted emerging markets following its merger with Schering-Plough
You may also be interested in...
Merck's Licensing & External Research Director Jennifer Hu On Choosing Partners In China: An Interview With PharmAsia News
Big pharma's rush into emerging markets is bringing more R&D to these markets, and as one of the key emerging markets China has attracted most multinational companies to set their R&D and licensing footprint here. Jennifer Hu, Merck's director of licensing and external research, recently shared her thoughts with PharmAsia News' Shanghai bureau about Merck's partnering and licensing strategy in China.
Merck's Licensing & External Research Director Jennifer Hu On Choosing Partners In China: An Interview With PharmAsia News
Big pharma's rush into emerging markets is bringing more R&D to these markets, and as one of the key emerging markets China has attracted most multinational companies to set their R&D and licensing footprint here. Jennifer Hu, Merck's director of licensing and external research, recently shared her thoughts with PharmAsia News' Shanghai bureau about Merck's partnering and licensing strategy in China.
GSK Sees Emerging Market Opportunity In Thinking Locally, Developing Locally
SINGAPORE - GSK APJEM R&D is pretty hefty as far as acronyms go, but GlaxoSmithKline's Judith Hills wants to make sure observers do not over look the research and development title in the new GSK division